Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: liu g. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Solomon BJ, Bauer TM, K Mok TS, Liu G, Mazieres J, Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: liu g. Future Oncol. 2023 May;19(14):961-973. doi: 10.2217/fon-2022-1289. Epub 2023 Jun 12. Future Oncol. 2023. PMID: 37306090 Free article. Review.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, Cortinovis D, Le AT, Huang D, Liu G, Cappuzzo F, Reyes Contreras J, Reck M, Palmero R, Mak MP, Hu Y, Morris S, Höglander E, Connors M, Biggane AM, Vollan HK, Peters S. Lee SM, et al. Among authors: liu g. Lancet. 2023 Aug 5;402(10400):451-463. doi: 10.1016/S0140-6736(23)00774-2. Epub 2023 Jul 6. Lancet. 2023. PMID: 37423228 Clinical Trial.
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.
Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. Rupp M, et al. Among authors: liu g. Curr Oncol. 2023 Jul 8;30(7):6559-6574. doi: 10.3390/curroncol30070481. Curr Oncol. 2023. PMID: 37504341 Free PMC article.
Understanding the patient perspective on research access to national health records databases for conduct of randomized registry trials.
Avram R, Marquis-Gravel G, Simard F, Pacheco C, Couture É, Tremblay-Gravel M, Desplantie O, Malhamé I, Bibas L, Mansour S, Parent MC, Farand P, Harvey L, Lessard MG, Ly H, Liu G, Hay AE, Marc Jolicoeur E. Avram R, et al. Among authors: liu g. Int J Cardiol. 2018 Jul 1;262:110-116. doi: 10.1016/j.ijcard.2017.12.074. Int J Cardiol. 2018. PMID: 29706388
Comparing Sonazoid contrast-enhanced ultrasound to contrast-enhanced CT and MRI for differentially diagnosing renal lesions: a prospective multicenter study.
Zhao QX, Wu C, Tan S, Yang Y, Cui XW, Dietrich CF, Yang B, Xu CL, Gao YY, Xie MX, Wu CJ, Liu LP, Wang XH, Ling-Hu RZ, Wang N, Wang F, Wang XL, Liu GY, Yu XL, Yu J, Cheng ZG, Liang P. Zhao QX, et al. Among authors: liu gy. World J Urol. 2024 May 8;42(1):302. doi: 10.1007/s00345-024-04885-7. World J Urol. 2024. PMID: 38720010
32,857 results
You have reached the last available page of results. Please see the User Guide for more information.